Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis

Conclusion: MG is a serious and rare adverse reaction to nivolumab. Nivolumab-induced MG should be timely and correctly identified, and immunotherapy should be given.

http://link.springer.com/10.1007/s10637-023-01347-6

Source: Investigational New Drugs - March 29, 2023 Category: Drugs & Pharmacology Source Type: research